AI

Asif Ikbal Khan

Active Director Director DIN 01420441
DIN 01420441 First appointment May 2005 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2005
Shareholding value •••• Premium profile

About Asif Ikbal Khan

Data last updated:

Asif Ikbal Khan is a Director at Relife Drugs Private Limited (since 2005). The company operates in Pharma. Relife Drugs Private Limited reported revenue of ₹1.55 Cr (FY 2025).

DIN 01420441
Primary Designation Director
Industry Pharma
First Appointment 30 May 2005
Oldest Company Age 21 yrs
Largest company Relife Drugs Private Limited · ₹1.55 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Relife Drugs Private Limited U51397UP2005PTC030071
Director30 May 20052005₹1.55 Cr (FY 2025)Active

Board colleagues of Asif Ikbal Khan

Directorship timeline

Open interactive timeline →
Relife Drugs Private Limited
Premium access

Shareholding and investment profile for Asif Ikbal Khan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Asif Ikbal Khan

Asif Ikbal Khan currently holds 1 directorship: Relife Drugs Private Limited (Director, since 30 May 2005, revenue ₹1.55 Cr (FY 2025)).

Asif Ikbal Khan was first appointed on 30 May 2005 as Director at Relife Drugs Private Limited.

The current boards of Asif Ikbal Khan's companies include Madhuri Sharma (Relife Drugs Private Limited), Ravi Praksh Sharma (Relife Drugs Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available